Skip to content

Changes of blood pressure and hemodynamic parameters after oral magnesium supplementation in patients with essential arterial hypertension

Changes of blood pressure and hemodynamic parameters after oral magnesium supplementation in patients with essential arterial hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017081535716N1
Enrollment
48
Registered
2017-09-22
Start date
2014-09-17
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential (primary) hypertension. High blood pressure, Hypertension (arterial)(benign)(essential)(malignant)(primary)(systemic)

Interventions

Daily oral supplementation with 300 mg of magnesium in the form of magnesium-oxide granules ("Magnezijum 300 Direkt" Hermes Arzneimittel GmbH, Germany) during one month at home. The granules were diss
Treatment - Other

Sponsors

-
Lead Sponsor

Eligibility

Sex/Gender
All
Age
24 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:age 24-65; essential arterial hypertention; unchanged antihipertensive therapy for at least one month; Exclusion criteria: renal diseases, gastrointestinal diseases, diabetes mellitus, diseases od adrenal, thyroid and parathyroid glands, angina pectoris, congestive heart failure, aortic coarctation, food and drugs allergy, pregnancy, lactation, myocardial infarction, coronary revascularisation, transitory ischemic attack, oral intake of magnesium supplements in the last one month

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Blood pressure (mm Hg). Timepoint: Before and after intervention. Method of measurement: Sphygmomanometer and Impedance cardiography.;Heart rate (beats per minute). Timepoint: Before and after intervention. Method of measurement: Impedance cardiography.;Thoracic fluid content (L/kOhm). Timepoint: Before and after intervention. Method of measurement: Impedance cardiography.;Stroke Volume (mL). Timepoint: Before and after intervention. Method of measurement: Impedance cardiography.;Stroke index (mL/m2). Timepoint: Before and after intervention. Method of measurement: Impedance cardiography.;Cardiac output (L/min). Timepoint: Before and after intervention. Method of measurement: Impedance cardiography.;Cardiac index (L/(min*m2). Timepoint: Before and after intervention. Method of measurement: Impedance cardiography.;Acceleration index (L/100/s2). Timepoint: Before and after intervention. Method of measurement: Impedance cardiography.;Left cardiac work index (kg*m/m²). Timepoint: Before and after intervention. Method of measurement: Impedance cardiography.;Systemic vascular resistance index (dyn*s*m2/cm5). Timepoint: Before and after intervention. Method of measurement: Impedance cardiography.

Secondary

MeasureTime frame
-. Timepoint: -. Method of measurement: -.

Countries

Serbia and Montenegro

Contacts

Public ContactNikolina Banjanin

Institute of Hygiene and Medical Ecology, Faculty of Medicine, University of Belgrade

nikolina.banjanin@med.bg.ac.rs00381113612762

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026